PTCT PTC THERAPEUTICS, INC.: institutional ownership and insider trading
400 funds reported holding $9.48B of PTC THERAPEUTICS, INC. in their latest 13F filings; in Q2 2026 funds net bought $404M, with 71 new positions and 44 funds selling out; over the last 12 months insiders bought $0 and sold $57.9M on the open market; over its last four quarters it reported revenue of $1.01B and net income of −$38.0M.
PTCT revenue and earnings
- Quarter ended Jun 30, 2026: revenue $361M, net income $83.5M, EPS 0.92
- Quarter ended Mar 31, 2026: revenue $273M, net income −$2.81M, EPS -0.03
- Quarter ended Dec 31, 2025: revenue $165M, net income −$135M, EPS -1.63
- Quarter ended Sep 30, 2025: revenue $211M, net income $15.9M, EPS 0.20
Famous investors holding PTCT
- Renaissance Technologies (Renaissance Technologies): $59.0M, 0.1% of the portfolio
- D. E. Shaw (D. E. Shaw & Co.): $126M, 0.1% of the portfolio
- Ken Griffin (Citadel Advisors): $62.5M, 0.0% of the portfolio
- Izzy Englander (Millennium Management): $3.79M, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $869K, 0.0% of the portfolio
Largest institutional holders of PTCT
- BlackRock, Inc. (BLK) — $1.14B
- VANGUARD GROUP INC — $669M
- RTW INVESTMENTS, LP — $632M
- Jupiter Topco LLC — $590M
- JANUS HENDERSON GROUP PLC (JHG) — $490M
- VANGUARD PORTFOLIO MANAGEMENT LLC — $402M
- STATE STREET CORP (STT, STT-PG) — $375M
- WELLINGTON MANAGEMENT GROUP LLP — $337M
- VANGUARD CAPITAL MANAGEMENT LLC — $305M
- GEODE CAPITAL MANAGEMENT, LLC — $180M
Recent PTCT insider trades
- Oct 14, 2026: Schmertzler Michael sold 2,500 shares ($149K)
- Oct 9, 2026: Boulding Mark Elliott sold 192 shares ($12.3K)
- Oct 7, 2026: Schmertzler Michael sold 2,500 shares ($158K)
- Oct 6, 2026: Boulding Mark Elliott sold 2,073 shares ($133K)
5%+ owners
- JANUS HENDERSON GROUP PLC: 8.7% (Schedule 13G/A, filed May 15, 2026)
- Vanguard Portfolio Management: 5.9% (Schedule 13G, filed Apr 29, 2026)
- Vanguard Capital Management: 5.2% (Schedule 13G, filed Apr 30, 2026)